See more : Bangkok Bank Public Company Limited (BKKPF) Income Statement Analysis – Financial Results
Complete financial analysis of SWK Holdings Corporation (SWKH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SWK Holdings Corporation, a leading company in the Asset Management industry within the Financial Services sector.
You may be interested
- Chemplast Sanmar Limited (CHEMPLASTS.NS) Income Statement Analysis – Financial Results
- Fincantieri S.p.A. (0QWN.L) Income Statement Analysis – Financial Results
- KCD INDUSTRIES INDIA LIMITED (KCDGROUP.BO) Income Statement Analysis – Financial Results
- Lakshmi Machine Works Limited (LAXMIMACH.NS) Income Statement Analysis – Financial Results
- Enservco Corporation (ENSV) Income Statement Analysis – Financial Results
SWK Holdings Corporation (SWKH)
About SWK Holdings Corporation
SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. In addition, the company engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Further, it intends to out-license its internal product pipeline to create novel formulations using its proprietary technology to develop treatments for patients and caregivers. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 37.76M | 41.48M | 56.16M | 36.71M | 30.75M | 25.99M | 37.49M | 22.38M | 23.46M | 17.40M | 6.45M | 637.00K | 0.00 | 0.00 | 45.26M | 65.22M | 60.79M | 54.03M | 43.13M | 48.90M | 61.01M | 79.09M | 86.87M | 119.25M | 14.10M | 2.00M |
| Cost of Revenue | 3.44M | 6.95M | 7.35M | 4.27M | 1.18M | 0.00 | 0.00 | 0.00 | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.54M | 20.69M | 17.24M | 12.90M | 11.74M | 11.94M | 12.83M | 32.65M | 50.61M | 50.05M | 5.40M | 400.00K |
| Gross Profit | 34.32M | 34.53M | 48.81M | 32.44M | 29.57M | 25.99M | 37.49M | 22.38M | 23.45M | 17.40M | 6.45M | 637.00K | 0.00 | 0.00 | 28.72M | 44.53M | 43.55M | 41.13M | 31.39M | 36.96M | 48.18M | 46.44M | 36.26M | 69.20M | 8.70M | 1.60M |
| Gross Profit Ratio | 90.90% | 83.24% | 86.92% | 88.37% | 96.18% | 100.00% | 100.00% | 100.00% | 99.96% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 63.45% | 68.28% | 71.64% | 76.13% | 72.78% | 75.59% | 78.97% | 58.72% | 41.74% | 58.03% | 61.70% | 80.00% |
| Research & Development | 0.00 | 6.95M | 7.35M | 4.27M | 1.18M | 0.24 | 0.88 | 0.64 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.85M | 13.82M | 12.65M | 10.77M | 13.23M | 19.50M | 21.44M | 25.93M | 35.56M | 42.72M | 12.90M | 2.30M |
| General & Administrative | 11.23M | 12.96M | 13.62M | 10.55M | 7.43M | 4.88M | 4.10M | 2.83M | 3.38M | 3.28M | 1.75M | 2.24M | 1.55M | 1.76M | 8.70M | 10.57M | 0.00 | 0.00 | 11.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.19M | 22.30M | 0.00 | 0.00 | 17.67M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.23M | 12.96M | 13.62M | 10.55M | 7.43M | 4.88M | 4.10M | 2.83M | 3.38M | 3.28M | 1.75M | 2.24M | 1.55M | 1.76M | 17.89M | 32.87M | 37.16M | 29.80M | 29.09M | 33.24M | 38.26M | 50.48M | 90.85M | 107.13M | 26.20M | 4.50M |
| Other Expenses | 8.44M | -862.00K | 4.06M | 12.09M | 7.16M | 6.18M | -5.22M | 1.66M | 10.85M | -129.00K | -60.00K | 0.00 | 0.00 | 0.00 | 5.06M | 500.00K | 288.00K | 133.00K | 6.46M | 2.41M | 7.32M | 76.42M | 746.99M | 896.75M | 82.00M | 1.50M |
| Operating Expenses | 19.67M | 19.05M | 17.68M | 22.64M | 14.59M | 11.06M | 4.10M | 4.49M | 14.23M | 3.28M | 1.75M | 2.24M | 1.55M | 1.76M | 35.79M | 47.19M | 50.10M | 40.70M | 48.78M | 55.15M | 67.02M | 152.83M | 873.39M | 1.05B | 121.10M | 8.30M |
| Cost & Expenses | 19.35M | 26.01M | 25.03M | 26.91M | 15.77M | 11.06M | 4.10M | 4.49M | 14.23M | 3.28M | 1.75M | 2.24M | 1.55M | 1.76M | 52.33M | 67.88M | 67.34M | 53.60M | 60.52M | 67.08M | 79.85M | 185.48M | 924.00M | 1.10B | 126.50M | 8.70M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.84M | 17.53M | 10.00K | 49.00K | 158.00K | 254.00K | 275.00K | 7.00K | 27.00K | 87.00K | 172.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.85M | 340.00K | 374.00K | 455.00K | 338.00K | 160.00K | 0.00 | 0.00 | 381.00K | 589.00K | 68.00K | 158.00K | 254.00K | 275.00K | 978.00K | 369.00K | 858.00K | 207.00K | 88.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.91M | 26.12M | 22.92M | 28.08M | 14.10M | 11.61M | 5.22M | 3.90M | 10.00K | 3.00K | 2.00K | 5.00K | 2.00K | 275.00K | 1.69M | 1.78M | 1.30M | 1.59M | 2.46M | 6.82M | 15.41M | 30.55M | 153.61M | 896.75M | 82.00M | 1.50M |
| EBITDA | 19.04M | 12.43M | 37.45M | 21.90M | 19.93M | 13.89M | 42.77M | 17.89M | -326.00K | 7.95M | 4.44M | -1.60M | -1.55M | -177.00K | 1.69M | -1.51M | -5.25M | 1.59M | -17.86M | -12.59M | -9.30M | -75.84M | -683.52M | -2.17B | -30.60M | -11.00M |
| EBITDA Ratio | 50.42% | 44.13% | 62.66% | 59.65% | 64.83% | 53.46% | 114.09% | 79.95% | 39.40% | 81.25% | 71.88% | -250.86% | 0.00% | 0.00% | -11.88% | -1.31% | -7.75% | 8.55% | -19.07% | -14.37% | -2.32% | -33.94% | 25.20% | 1,687.94% | -170.92% | -270.00% |
| Operating Income | 14.65M | 15.48M | 31.13M | 9.81M | 14.98M | 14.93M | 33.39M | 17.89M | 2.60M | 14.13M | 4.70M | -1.60M | -1.55M | -1.76M | -8.42M | -3.24M | -7.12M | -271.00K | -17.86M | -21.58M | -20.55M | -101.31M | -939.62M | -977.40M | -112.40M | -6.70M |
| Operating Income Ratio | 38.80% | 37.31% | 55.43% | 26.71% | 48.71% | 57.44% | 89.06% | 79.95% | 11.07% | 81.18% | 72.90% | -251.65% | 0.00% | 0.00% | -18.60% | -4.97% | -11.70% | -0.50% | -41.41% | -44.13% | -33.68% | -128.09% | -1,081.64% | -819.64% | -797.16% | -335.00% |
| Total Other Income/Expenses | -37.00K | -477.00K | 1.88M | -22.05M | -3.93M | -673.00K | -9.38M | -7.49M | -3.69M | -824.00K | -209.00K | 158.00K | 453.00K | 1.03M | 43.31M | -411.00K | -739.00K | -1.94M | 88.00K | 128.00K | -314.00K | 913.00K | -705.42M | -2.09B | -6.30M | 6.40M |
| Income Before Tax | 14.61M | 9.49M | 33.01M | 3.67M | 16.84M | 6.24M | 24.00M | 10.40M | -1.09M | 13.30M | 4.49M | -1.45M | -1.09M | -727.00K | 34.90M | -3.65M | -7.85M | -2.21M | -17.77M | -21.45M | -20.86M | -150.31M | -1.65B | -3.07B | -118.70M | -6.50M |
| Income Before Tax Ratio | 38.70% | 22.88% | 58.79% | 9.98% | 54.78% | 24.00% | 64.03% | 46.48% | -4.65% | 76.44% | 69.66% | -226.84% | 0.00% | 0.00% | 77.10% | -5.60% | -12.92% | -4.08% | -41.20% | -43.87% | -34.19% | -190.04% | -1,893.68% | -2,575.22% | -841.84% | -325.00% |
| Income Tax Expense | -1.27M | -4.00M | 7.08M | -1.54M | -6.99M | 42.00K | 15.75M | -21.64M | 3.27M | -10.30M | -9.84M | -24.00K | -26.00K | -20.00K | 3.00K | 5.00K | 167.00K | 219.00K | 196.00K | 314.00K | 318.00K | -10.28M | 105.76M | 2.09B | 6.40M | -400.00K |
| Net Income | 15.89M | 13.49M | 25.93M | 5.20M | 23.83M | 6.20M | 3.05M | 28.89M | -7.37M | 20.77M | 12.86M | -1.42M | -1.07M | -707.00K | 34.89M | -3.66M | -8.02M | -2.43M | -17.97M | -21.77M | -20.97M | -96.11M | -942.90M | -3.07B | -118.80M | -6.30M |
| Net Income Ratio | 42.07% | 32.52% | 46.17% | 14.17% | 77.50% | 23.84% | 8.13% | 129.08% | -31.42% | 119.34% | 199.50% | -223.08% | 0.00% | 0.00% | 77.10% | -5.60% | -13.19% | -4.49% | -41.66% | -44.52% | -34.37% | -121.52% | -1,085.41% | -2,575.22% | -842.55% | -315.00% |
| EPS | 1.26 | 1.05 | 2.03 | 0.40 | 1.85 | 0.47 | 0.23 | 2.22 | -0.57 | 3.20 | 3.10 | -0.34 | -0.26 | -0.17 | 8.50 | -0.89 | -2.16 | -0.70 | -5.83 | -7.52 | -8.72 | -42.90 | -686.09 | -3.96K | -773.72 | -100.67 |
| EPS Diluted | 1.25 | 1.05 | 2.02 | 0.40 | 1.85 | 0.47 | 0.23 | 2.22 | -0.57 | 3.20 | 3.10 | -0.34 | -0.26 | -0.17 | 8.50 | -0.89 | -2.16 | -0.70 | -5.83 | -7.52 | -8.72 | -42.90 | -686.09 | -3.96K | -773.72 | -100.67 |
| Weighted Avg Shares Out | 12.65M | 12.84M | 12.80M | 12.85M | 12.91M | 13.05M | 13.04M | 13.02M | 12.93M | 6.49M | 4.13M | 4.12M | 4.12M | 4.12M | 4.12M | 4.12M | 3.71M | 3.46M | 3.08M | 2.90M | 2.40M | 2.24M | 1.37M | 776.10K | 153.54K | 62.58K |
| Weighted Avg Shares Out (Dil) | 12.70M | 12.88M | 12.83M | 12.86M | 12.91M | 13.05M | 13.04M | 13.02M | 12.99M | 6.49M | 4.14M | 4.12M | 4.12M | 4.12M | 4.12M | 4.12M | 3.71M | 3.46M | 3.08M | 2.90M | 2.40M | 2.24M | 1.37M | 776.10K | 153.54K | 62.58K |
Enteris BioPharma Completes Expansion of Manufacturing Facility and Announces Launch of CDMO Business Segment
BOONTON, N.J., May 3, 2021 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), today announced the expansion of its Boonton, NJ...
Industrial Stocks Earnings to Watch on Apr 28: SWK, ROK, IR, AVY
The impacts of improvement in manufacturing activities and the pandemic-led tailwinds as well as woes are expected to get reflected in industrial stocks' results for the January-March quarter. SWK, ROK, IR & AVY are due for release on Apr 28.
New Strong Buy Stocks for April 7th
New Strong Buy Stocks for April 7th
SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full-Year 2020
DALLAS, March 31, 2021 /PRNewswire/ -- Corporate Highlights Closed four transactions in 2020 deploying $34.8 million; additional $8.1 million deployed to existing borrowers Income producing assets as of December 31, 2020 reached an all-time high of $206.0 million, accompanied by...
Sincerus Pharmaceuticals Completes Financing With SWK To Support The Demand For Its Customized Dermatologic Medicines
POMPANO BEACH, Fla., March 24, 2021 /PRNewswire/ -- Sincerus Pharmaceuticals, the parent company of Prescriber's Choice and Sincerus Florida, today announced the completion of a major new round of growth financing with SWK Holdings Corporation (Nasdaq: SWKH), representing what is by...
SWK Holdings to Present at Maxim Group's Emerging Growth Virtual Conference
DALLAS, March 15, 2021 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that Winston Black, Chairman and CEO of SWK Holdings, will present during the Maxim...
SWKH vs. LU: Which Stock Should Value Investors Buy Now?
SWKH vs. LU: Which Stock Is the Better Value Option?
SWKH vs. RCM: Which Stock Is the Better Value Option?
SWKH vs. RCM: Which Stock Is the Better Value Option?
Industrial Stocks Earnings Due on Jan 28: SWK, DOV, PNR & AIT
Industrial stocks' results for the October-December quarter are anticipated to reflect the impacts of improved operating conditions, the pandemic-led woes and others. SWK, DOC, PNR & AIT are due for release on Jan 28.
Flowonix Medical, Inc. and SWK Holdings Corporation Announce Closing of $33 Million Financing
MOUNT OLIVE, N.J., Jan. 4, 2021 /PRNewswire/ -- Flowonix Medical, Inc., a medical device company focused on providing advanced, implantable drug delivery solutions and SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small and...
Source: https://incomestatements.info
Category: Stock Reports